Search Results - "KANTHOU, Chryso"

Wearable Insulin Biosensors for Diabetes Management: Advances and Challenges by Psoma, Sotiria D, Kanthou, Chryso

“…We present a critical review of the current progress in wearable insulin biosensors. For over 40 years, glucose biosensors have been used for diabetes…”
Get full text

Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies by Kanthou, Chryso, Tozer, Gillian M.

“…Summary Vascular disrupting agents (VDAs) are a relatively new group of ‘vascular targeting’ agents that exhibit selective activity against established tumour…”
Get full text

Sydnone Cycloaddition Route to Pyrazole-Based Analogs of Combretastatin A4 by Brown, Andrew W, Fisher, Matthew, Tozer, Gillian M, Kanthou, Chryso, Harrity, Joseph P. A

“…The combretastatins are an important class of tubulin-binding agents. Of this family, a number of compounds are potent tumor vascular disrupting agents (VDAs)…”
Get full text

The Vitamin K-Dependent Anticoagulant Factor, Protein S, Regulates Vascular Permeability by Joussaume, Aurélie, Kanthou, Chryso, Pardo, Olivier E, Karayan-Tapon, Lucie, Benzakour, Omar, Dkhissi, Fatima

“…Protein S (PROS1) is a vitamin K-dependent anticoagulant factor, which also acts as an agonist for the TYRO3, AXL, and MERTK (TAM) tyrosine kinase receptors…”
Get full text

Differential Expression of VEGFA Isoforms Regulates Metastasis and Response to Anti-VEGFA Therapy in Sarcoma by English, William R, Lunt, Sarah Jane, Fisher, Matthew, Lefley, Diane V, Dhingra, Mohit, Lee, Yu-Chin, Bingham, Karina, Hurrell, Jack E, Lyons, Scott K, Kanthou, Chryso, Tozer, Gillian M

“…Elevated plasma concentrations of soluble VEGFA isoforms are associated with poor prognosis in parallel with improved response to treatment with the anti-VEGFA…”
Get full text

The tumor vascular targeting agent combretastatin A–4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells by Kanthou, Chryso, Tozer, Gillian M.

“…Combretastatin A–4-phosphate (CA-4-P) is a tubulin-binding compound currently in clinical trial as a tumor vascular-targeting agent. In endothelial cells,…”
Get full text

The influence of hypoxia and energy depletion on the response of endothelial cells to the vascular disrupting agent combretastatin A-4-phosphate by Holmes, Toby, Brown, Andrew W., Suggitt, Marie, Shaw, Lucy A., Simpson, Lucy, Harrity, Joseph P. A., Tozer, Gillian M., Kanthou, Chryso

“…Combretastatin A-4 phosphate (CA4P) is a microtubule-disrupting tumour-selective vascular disrupting agent (VDA). CA4P activates the actin-regulating…”
Get full text

Radiation Effects on the Cytoskeleton of Endothelial Cells and Endothelial Monolayer Permeability by Gabryś, Dorota, M.D, Greco, Olga, Ph.D, Patel, Gaurang, B.Sc, Prise, Kevin M., Ph.D, Tozer, Gillian M., Ph.D, Kanthou, Chryso, Ph.D

“…Purpose To investigate the effects of radiation on the endothelial cytoskeleton and endothelial monolayer permeability and to evaluate associated signaling…”
Get full text

Do anti-angiogenic VEGF (VEGFxxxb) isoforms exist? A cautionary tale by Harris, Sheila, Craze, Madeleine, Newton, Jillian, Fisher, Matthew, Shima, David T, Tozer, Gillian M, Kanthou, Chryso

“…Splicing of the human vascular endothelial growth factor-A (VEGF-A) gene has been reported to generate angiogenic (VEGFxxx) and anti-angiogenic (VEGFxxxb)…”
Get full text

The endothelial cytoskeleton as a target of electroporation-based therapies by Kanthou, Chryso, Kranjc, Simona, Sersa, Gregor, Tozer, Gill, Zupanic, Anze, Cemazar, Maja

“…Electroporation-based therapies, such as electrochemotherapy and electrogene therapy, result in the disruption of blood vessel networks in vivo and cause…”
Get full text

Systemic antiangiogenic activity of cationic poly-L-lysine dendrimer delays tumor growth by Al-Jamal, Khuloud T, Al-Jamal, Wafa' T, Akerman, Simon, Podesta, Jennifer E, Yilmazer, Açelya, Turton, John A, Bianco, Alberto, Vargesson, Neil, Kanthou, Chryso, Florence, Alexander T, Tozer, Gillian M, Kostarelos, Kostas

“…This study describes the previously unreported intrinsic capacity of poly-L-lysine (PLL) sixth generation (G₆) dendrimer molecules to exhibit systemic…”
Get full text

Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform-Producing Tumors by TOZER, Gillian M, AKERMAN, Simon, PETTYJOHN, Katie L, PRISE, Vivien E, REYES-ALDASORO, Constantino C, RUHRBERG, Christiana, SHIMA, David T, KANTHOU, Chryso, CROSS, Neil A, BARBER, Paul R, BJÖRNDAHL, Meit A, GRECO, Olga, HARRIS, Sheila, HILL, Sally A, HONESS, Davina J, IRESON, Christopher R

“…Tubulin-binding vascular-disrupting agents (VDA) are currently in clinical trials for cancer therapy but the factors that influence tumor susceptibility to…”
Get full text

Tumour cells expressing single VEGF isoforms display distinct growth, survival and migration characteristics by Kanthou, Chryso, Dachs, Gabi U, Lefley, Diane V, Steele, Andrew J, Coralli-Foxon, Claudia, Harris, Sheila, Greco, Olga, Dos Santos, Sofia A, Reyes-Aldasoro, Constantino C, English, William R, Tozer, Gillian M

“…Vascular endothelial growth factor-A (VEGF) is produced by most cancer cells as multiple isoforms, which display distinct biological activities. VEGF plays an…”
Get full text

Expression of vascular endothelial growth factor receptors in smooth muscle cells by Ishida, Atsushi, Murray, Jacqueline, Saito, Yuji, Kanthou, Chryso, Benzakour, Omar, Shibuya, Masabumi, Wijelath, Errol S.

“…Vascular Endothelial Growth Factor (VEGF) has been typically considered to be an endothelial‐specific growth factor. However, it was recently demonstrated that…”
Get full text

Targeting the vasculature of tumours: combining VEGF pathway inhibitors with radiotherapy by Kanthou, Chryso, Tozer, Gillian

“…The development of blood vessels by the process of angiogenesis underpins the growth and metastasis of many tumour types. Various angiogenesis inhibitors…”
Get full text

Anti-vascular agent Combretastatin A-4-P modulates hypoxia inducible factor-1 and gene expression by Dachs, Gabi U, Steele, Andrew J, Coralli, Claudia, Kanthou, Chryso, Brooks, Andrew C, Gunningham, Sarah P, Currie, Margaret J, Watson, Ally I, Robinson, Bridget A, Tozer, Gillian M

“…A functional vascular network is essential for the survival, growth and spread of solid tumours, making blood vessels a key target for therapeutic strategies…”
Get full text

Mechanisms of cytotoxicity induced by horseradish peroxidase/indole-3-acetic acid gene therapy by Greco, Olga, Dachs, Gabi U., Tozer, Gillian M., Kanthou, Chryso

“…We have previously proposed the horseradish peroxidase (HRP) and the non‐toxic plant hormone indole‐3‐acetic acid (IAA) as a novel system for gene‐directed…”
Get full text

Induction of Vascular SMC Proliferation by Urokinase Indicates a Novel Mechanism of Action in Vasoproliferative Disorders by Kanse, Sandip M, Benzakour, Omar, Kanthou, Chryso, Kost, Christine, Lijnen, H. Roger, Preissner, Klaus T

“…The urokinase-type plasminogen activator (UPA) and its receptor are expressed in the vasculature and are involved in cell migration and remodeling of the…”
Get full text

Disrupting tumour blood vessels by Tozer, Gillian M, Kanthou, Chryso, Baguley, Bruce C

“…Low-molecular-weight vascular-disrupting agents (VDAs) cause a pronounced shutdown in blood flow to solid tumours, resulting in extensive tumour-cell necrosis,…”
Get full text

Rational Design of Cholesterol Derivative for Improved Stability of Paclitaxel Cationic Liposomes by Monpara, Jasmin, Kanthou, Chryso, Tozer, Gillian M., Vavia, Pradeep R.

“…Purpose This work explores synthesis of novel cholesterol derivative for the preparation of cationic liposomes and its interaction with Paclitaxel (PTX) within…”
Get full text